Tumoral heterogeneity of hepatic cholangiocarcinomas revealed by MALDI imaging mass spectrometry

Cholangiocarcinoma (CC) is the second most common primary malignancy of the liver. Although all CC derive from biliary epithelial cells, two main subtypes, hilar (H), and peripheral (P) CC are described. The objective of the study was to compare, using MALDI imaging mass spectrometry (MALDI IMS), in situ proteomic profiles of H‐ and P‐CC in order to assess whether these subtypes may express different markers and to describe their respective localizations. Twenty‐seven CC (16 P‐CC and 11 H‐CC) were subjected to MALDI IMS. Proteomic data were submitted to a dedicated cross‐classification comparative design, enabling comparison of the entire generated spectra. Immunohistochemistry was performed for validation. Comparative analysis yielded a list of 19 differential protein peaks for the two subtypes, 14 of which were overexpressed in H‐CC and five in P‐CC. Among H‐CC protein markers, most discriminant were human neutrophil peptides 1–3 that were expressed mainly by tumor cells and S100 proteins (A6 and A11) that were restricted to the stromal area. In P‐CC, thymosin β4 was diffusely overexpressed. These results highlight the potential of MALDI IMS to discover new relevant biomarkers of CC and to characterize the heterogeneity of the two different subtypes.

[1]  J. Llovet,et al.  Intrahepatic cholangiocarcinoma: pathogenesis and rationale for molecular therapies , 2013, Oncogene.

[2]  Theodore Alexandrov,et al.  Imaging mass spectrometry reveals modified forms of histone H4 as new biomarkers of microvascular invasion in hepatocellular carcinomas , 2013, Hepatology.

[3]  Rameen Beroukhim,et al.  Integrative molecular analysis of intrahepatic cholangiocarcinoma reveals 2 classes that have different outcomes. , 2013, Gastroenterology.

[4]  Heinz Höfler,et al.  MALDI imaging mass spectrometry in cancer research: combining proteomic profiling and histological evaluation. , 2013, Clinical biochemistry.

[5]  Jonas Bergquist,et al.  MALDI imaging of post‐mortem human spinal cord in amyotrophic lateral sclerosis , 2013, Journal of neurochemistry.

[6]  A. Sümer,et al.  Human neutrophil peptides 1, 2 and 3 (HNP 1–3): elevated serum levels in colorectal cancer and novel marker of lymphatic and hepatic metastasis , 2013, Human & experimental toxicology.

[7]  Theodore Alexandrov,et al.  New analysis workflow for MALDI imaging mass spectrometry: application to the discovery and identification of potential markers of childhood absence epilepsy. , 2012, Journal of proteome research.

[8]  M. Kriegsmann,et al.  MALDI MS imaging as a powerful tool for investigating synovial tissue , 2012, Scandinavian journal of rheumatology.

[9]  Stefan K. Maier,et al.  MALDI Imaging Mass Spectrometry for In Situ Proteomic Analysis of Preneoplastic Lesions in Pancreatic Cancer , 2012, PloS one.

[10]  Itzhak Avital,et al.  Genomic and genetic characterization of cholangiocarcinoma identifies therapeutic targets for tyrosine kinase inhibitors. , 2012, Gastroenterology.

[11]  S. Rauser,et al.  MALDI imaging identifies prognostic seven-protein signature of novel tissue markers in intestinal-type gastric cancer. , 2011, The American journal of pathology.

[12]  R. Caprioli,et al.  Multiplexed molecular descriptors of pressure ulcers defined by imaging mass spectrometry , 2011, Wound repair and regeneration : official publication of the Wound Healing Society [and] the European Tissue Repair Society.

[13]  Jean-Michel Camadro,et al.  Imaging mass spectrometry provides fingerprints for distinguishing hepatocellular carcinoma from cirrhosis. , 2011, Journal of proteome research.

[14]  Richard M Caprioli,et al.  Protein signatures for survival and recurrence in metastatic melanoma. , 2011, Journal of proteomics.

[15]  J. Albrethsen.  The first decade of MALDI protein profiling: a lesson in translational biomarker research. , 2011, Journal of proteomics.

[16]  R. Caprioli,et al.  Lung cancer diagnosis from proteomic analysis of preinvasive lesions. , 2011, Cancer research.

[17]  Michael Becker,et al.  Revisiting Rat Spermatogenesis with MALDI Imaging at 20-μm Resolution* , 2010, Molecular & Cellular Proteomics.

[18]  U. Schubert,et al.  Depicting the Spatial Distribution of Proteins in Human Tumor Tissue Combining SELDI and MALDI Imaging and Immunohistochemistry , 2010, The journal of histochemistry and cytochemistry : official journal of the Histochemistry Society.

[19]  Didier Samuel,et al.  Identification of Cellular Targets in Human Intrahepatic Cholangiocarcinoma Using Laser Microdissection and Accurate Mass and Time Tag Proteomics* , 2010, Molecular & Cellular Proteomics.

[20]  R. Caprioli,et al.  Identification of Markers of Taxane Sensitivity Using Proteomic and Genomic Analyses of Breast Tumors from Patients Receiving Neoadjuvant Paclitaxel and Radiation , 2010, Clinical Cancer Research.

[21]  川瀬 寛.  Differential LC-MS-based proteomics of surgical human cholangiocarcinoma tissues , 2010 .

[22]  A. Filipek,et al.  S100A6 - new facts and features. , 2009, Biochemical and biophysical research communications.

[23]  E. Solary,et al.  Human defensins as cancer biomarkers and antitumour molecules. , 2009, Journal of proteomics.

[24]  F. Inagaki,et al.  Differential LC-MS-based proteomics of surgical human cholangiocarcinoma tissues. , 2009, Journal of proteome research.

[25]  V. Paradis,et al.  Comparative protein expression profiles of hilar and peripheral hepatic cholangiocarcinomas. , 2009, Journal of hepatology.

[26]  D. Ward,et al.  Identification of macrophage migration inhibitory factor and human neutrophil peptides 1–3 as potential biomarkers for gastric cancer , 2009, British Journal of Cancer.

[27]  Bart J. A. Mertens,et al.  Biomarker discovery in MALDI-TOF serum protein profiles using discrete wavelet transformation , 2009, Bioinform..

[28]  G. Gores,et al.  Cholangiocarcinoma: Advances in pathogenesis, diagnosis, and treatment , 2008, Hepatology.

[29]  P. Chaurand,et al.  Monitoring Mouse Prostate Development by Profiling and Imaging Mass Spectrometry*S , 2008, Molecular & Cellular Proteomics.

[30]  F. Bosch,et al.  Proteomic analysis reveals successive aberrations in protein expression from healthy mucosa to invasive head and neck cancer , 2007, Oncogene.

[31]  S. Gammeltoft,et al.  Human neutrophil peptides 1, 2 and 3 are biochemical markers for metastatic colorectal cancer. , 2006, European journal of cancer.

[32]  Richard M Caprioli,et al.  Molecular imaging of thin mammalian tissue sections by mass spectrometry. , 2006, Current opinion in biotechnology.

[33]  A. Vlahou,et al.  Overexpression of α-defensin is associated with bladder cancer invasiveness , 2006 .

[34]  A. Vlahou,et al.  Overexpression of alpha-defensin is associated with bladder cancer invasiveness. , 2006, Urologic oncology.

[35]  U. Settmacher,et al.  Discovery and identification of alpha-defensins as low abundant, tumor-derived serum markers in colorectal cancer. , 2005, Gastroenterology.

[36]  W. Greenhalf,et al.  High nuclear S100A6 (Calcyclin) is significantly associated with poor survival in pancreatic cancer patients. , 2005, Cancer research.

[37]  Pierre Bedossa,et al.  Identification of a new marker of hepatocellular carcinoma by serum protein profiling of patients with chronic liver diseases , 2005, Hepatology.

[38]  Z. Halpern,et al.  An increasing incidence of cholangiocarcinoma: why? , 2004, Gastroenterology.

[39]  H. El‐Serag,et al.  The epidemiology of cholangiocarcinoma. , 2004, Seminars in liver disease.

[40]  P. Maxwell,et al.  Identification and overexpression of human neutrophil alpha-defensins (human neutrophil peptides 1, 2 and 3) in squamous cell carcinomas of the human tongue. , 2004, Oral oncology.

[41]  G. Gores.  PERSPECTIVES IN CLINICAL HEPATOLOGY Cholangiocarcinoma: Current Concepts and Insights , 2003 .

[42]  M. Tatsuta,et al.  Expression of S100A6 and S100A4 in Matched Samples of Human Colorectal Mucosa, Primary Colorectal Adenocarcinomas and Liver Metastases , 2002, Oncology.

[43]  M. Deeg,et al.  Human α-Defensins HNPs-1, -2, and -3 in Renal Cell Carcinoma : Influences on Tumor Cell Proliferation , 2002 .

[44]  M. Deeg,et al.  Human alpha-defensins HNPs-1, -2, and -3 in renal cell carcinoma: influences on tumor cell proliferation. , 2002, The American journal of pathology.

[45]  A. Bateman,et al.  The levels and biologic action of the human neutrophil granule peptide HP-1 in lung tumors , 1992, Peptides.